|
Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987
NASDAQ (RTTNews.com) – Targacept Inc. (TRGT) announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. After identifying an error in the application of the agreed statistical analysis plan, a reanalysis of the data … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study |
View full post on asthma – Google News